ARCH Venture Partners

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.

Kardigan is a pioneering heart health company dedicated to transforming cardiovascular drug development. It focuses on identifying and matching critical disease drivers with responsive patients from clinical trials, aiming to deliver curative medicines that go beyond symptom management, ultimately providing functional cures for cardiovascular diseases.

Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.

Bit.bio specializes in applying computational principles to biology, focusing on developing a scalable platform capable of producing consistent batches of every human cell. This enables more accurate research, drug discovery, and cell therapy applications.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

City Therapeutics is a biopharmaceutical company specializing in the development of next-generation small-interfering RNAs (siRNAs) to enhance RNA interference (RNAi) therapies. The company's pipeline comprises innovative RNAi therapeutics targeting diverse disease indications. City Therapeutics aims to improve and expand RNAi technology to achieve better patient outcomes, led by a team of experienced scientists and industry professionals committed to advancing the field of RNA interference.

Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Moleculent is a biotechnology company focused on advancing human health through technology-enabled products that utilize insights into the molecular basis of human biology. The company is dedicated to decoding human biology and aims to significantly enhance therapies and diagnostics by leveraging new scientific knowledge. Moleculent believes that a deeper understanding of molecular mechanisms, especially in relation to health and disease, will emerge over the next decade, paving the way for innovative healthcare solutions. Through its efforts, the company seeks to provide healthcare professionals with access to molecular science-based therapies and diagnostics that can improve patient care and outcomes.

Vilya is a biotechnology company focused on developing innovative drugs that precisely target the underlying biology of diseases. By leveraging advanced computational techniques, Vilya aims to create a new class of medicines that can efficiently navigate uncharted chemical spaces and generate novel molecular structures. These structures, which are designed to possess essential drug-like properties, can range in size between small molecules and antibodies. Vilya's platform is engineered to improve the drug discovery process, enabling more effective treatments by facilitating the disruption of protein-protein interactions and ensuring optimal movement through biological membranes. Through its pioneering approach, Vilya is dedicated to advancing therapeutic options for patients.

Slingshot Biosciences develops engineered synthetic cells to accelerate drug research and enable diagnostics and therapeutics. The company creates next-generation cellular tools that aim to simplify complex experiments, improve data standardization in cell analysis, and provide cost-effective solutions for research programs. Its work includes aligning cellular properties such as forward and side scatter of white blood cells to enable more consistent measurements and faster interpretation. By removing cold-chain barriers, Slingshot Biosciences seeks to broaden access to advanced diagnostics and therapeutics, supporting programs focused on neglected and rare diseases. Operating in the industrial synthetic biology space, the company concentrates on practical cellular technologies that can shorten development timelines and reduce costs for researchers.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.

Over millions and millions of years, a collection of reward systems

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

Proniras Corporation is a preclinical-stage biotechnology company based in Seattle, Washington, focused on developing innovative parenteral medical countermeasure drugs, particularly tezampanel, for treating seizures and brain injuries. Founded in 2016, the company has demonstrated preclinical efficacy in addressing nerve agent-induced seizures, particularly in studies involving exposure to soman, a highly toxic chemical weapon. By targeting the central nervous system, Proniras aims to develop novel small-molecule therapeutics for various neurological conditions characterized by high unmet medical needs. Their research is designed to provide medical researchers with valuable tools for advancing treatments in this critical area.

Basking Biosciences is developing a reversible thrombolytic therapy to restore blood flow to the brain during ischemic stroke, with the aim of preventing hemorrhage and long-term damage. The platform combines a primary agent that targets clot stability with a designed reversal agent that can be administered if bleeding occurs to neutralize the active compound and restore normal clotting, enabling treatment for acute ischemic stroke.

Accompany Health provides comprehensive in-home primary care, including chronic illness management and treatment of new symptoms, and coordinates care across the full patient journey. The company offers at-home and virtual care, with round-the-clock support to address health needs any time, day or night. It focuses on cultivating long-term relationships with patients, ensuring consistent access to care and a stable point of contact year after year. Accompany Health serves individuals with complex needs, including low-income populations, helping them manage health journeys effectively and improve outcomes. By combining clinical delivery with technology-enabled care coordination, the company aims to reduce barriers such as waiting rooms and lines and to provide dignified care that supports patients throughout ongoing management of chronic conditions and new symptoms.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company specializes in creating a profiling and engineering technology platform that leverages advanced artificial intelligence predictions to offer a comprehensive view of the epigenome in both health and disease states. This innovative approach aims to revolutionize therapy discovery and development, enabling healthcare providers to reprogram cells back to their healthy state.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

UltraDx Bio is a biotechnology company that specializes in single-molecule digital high-sensitivity protein detection technology.

Gate Bioscience is a biotechnology company focused on developing small molecule drugs aimed at treating challenging diseases by selectively eliminating harmful extracellular proteins at their source within cells. The company utilizes a unique library of molecular gates along with specialized secretion-focused assays and technologies, leveraging its deep understanding of the biology of the secretory pathway. This approach facilitates precise, rapid, and repeatable drug discovery, allowing for the potential to address a diverse array of diseases using a single therapeutic mechanism.

Magnet Biomedicine is a biotechnology company specializing in discovering novel molecular glues using its proprietary TrueGlue platform. This platform leverages advancements in human biology and proteomics to identify adhesives optimized for therapeutic effectiveness, enhancing selectivity and targeting previously challenging proteins across various disease areas such as cancer, cardiovascular disease, and immune disorders.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in drug discovery through advanced microfluidic technology. The company focuses on developing new therapies and innovative products by leveraging its unique platform, which allows for the precise and flexible control of thousands of droplets. This capability enables the combination of various cells, reporters, and reagents to conduct complex workflows without manual cell manipulation. By collaborating with major pharmaceutical companies and leading academic institutions, Lightcast Discovery seeks to enhance complex cell analysis and facilitate the discovery of new clinical approaches.

TFC Therapeutics is a biotechnology company focused on creating innovative biologics aimed at addressing critical factors in cancer recurrence and metastasis. The company develops technology that employs monoclonal antibodies designed to specifically bind to receptors on tumor-initiating cells, known as TMH cells. This targeted approach activates the immune system to effectively destroy these cells, offering new treatment possibilities for cancer within the healthcare sector. Through its research and development efforts, TFC Therapeutics seeks to contribute significantly to advancements in cancer therapy.

Bitterroot Bio specializes in developing innovative therapies for cardiovascular disease by harnessing the power of immunotherapy.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

OncoResponse is an immuno‑oncology biotechnology company that uses a proprietary human antibody platform to discover novel targets and develop fully human monoclonal antibodies for cancer treatment. By interrogating the adaptive immune system of patients who respond exceptionally well to checkpoint inhibition, the company identifies genuine human antibodies against high‑value targets linked with immunosuppressive myeloid biology. Its pipeline aims to alleviate tumor‑microenvironment immunosuppression and enhance immune activation, converting cold tumors into hot ones and providing new therapeutic options for patients.

Orbital Therapeutics develops innovative RNA-based medicines to enhance global health. Its platform integrates RNA technology, delivery techniques, data analytics, and automation to create a broad portfolio of treatments for various diseases.

Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for neurological disorders. The company focuses on creating transformational small-molecule therapies aimed at patients with central nervous system conditions. Leveraging foundational research in neuronal receptor biology, Rapport Therapeutics maps and targets specific neuronal receptor complexes, which are complex assemblies of proteins that include principal receptor subunits and receptor-associated proteins. These receptor-associated proteins are essential for regulating receptor expression and functionality, allowing the company to innovate in the treatment of neurological diseases.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Paratus Sciences focuses on advancing human health and health security by studying the biology of bats. It integrates cell biology, genomics, informatics, and large-scale data inputs to compare disease resistance patterns in bats with those in humans, aiming to develop therapeutics that mimic bats' adaptations.

Aera Therapeutics is a biotechnology company focused on advancing genetic medicines through its proprietary protein nanoparticle (PNP) delivery platform. This innovative platform utilizes endogenous human proteins derived from retroelements, which self-assemble into capsid-like structures capable of packaging and transferring nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to enhance the efficacy and reach of genetic therapies across various tissues and disease areas. Additionally, the company holds a licensed technology that features a therapeutic enzyme platform based on novel, compact, and programmable gene-editing enzymes, further expanding its capabilities in the field of genetic medicine.

Aera Therapeutics is a biotechnology company focused on advancing genetic medicines through its proprietary protein nanoparticle (PNP) delivery platform. This innovative platform utilizes endogenous human proteins derived from retroelements, which self-assemble into capsid-like structures capable of packaging and transferring nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to enhance the efficacy and reach of genetic therapies across various tissues and disease areas. Additionally, the company holds a licensed technology that features a therapeutic enzyme platform based on novel, compact, and programmable gene-editing enzymes, further expanding its capabilities in the field of genetic medicine.

IngredientWerks is a molecular farming company based in Woburn, Massachusetts, founded in 2022. It focuses on enhancing plant proteins to improve the taste and texture of plant-based foods by redesigning proteins to enable sustainable, cost-efficient production of food ingredients for the growing alternative protein market.

Slingshot Biosciences develops engineered synthetic cells to accelerate drug research and enable diagnostics and therapeutics. The company creates next-generation cellular tools that aim to simplify complex experiments, improve data standardization in cell analysis, and provide cost-effective solutions for research programs. Its work includes aligning cellular properties such as forward and side scatter of white blood cells to enable more consistent measurements and faster interpretation. By removing cold-chain barriers, Slingshot Biosciences seeks to broaden access to advanced diagnostics and therapeutics, supporting programs focused on neglected and rare diseases. Operating in the industrial synthetic biology space, the company concentrates on practical cellular technologies that can shorten development timelines and reduce costs for researchers.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.

Protillion Biosciences is a biotechnology company focused on transforming therapeutic antibody and drug discovery through its innovative protein engineering platform. This high-throughput platform is designed to streamline and enhance traditional methods of designing and developing protein-based drugs. By utilizing advanced techniques, Protillion aims to accelerate the research and development process for biologics, thereby enabling healthcare professionals to discover and bring new protein therapeutics to market more efficiently. The company's commitment to developing disruptive technology positions it as a key player in the evolving landscape of drug discovery and development.

SonoThera is a biotechnology company focused on developing innovative genetic therapies using ultrasound technology. The company's mission is to create non-viral genetic medicines that address the root causes of human diseases. SonoThera specializes in ultrasound-guided nonviral gene therapy, aiming to provide effective treatments for conditions that currently have suboptimal or no available treatments. By leveraging this approach, SonoThera seeks to enhance the health and quality of life for millions of people worldwide.

Founded in 2015, Carrick Therapeutics is a biopharmaceutical company based in Dublin, Ireland. It specializes in developing innovative cancer therapeutics that target molecular pathways driving aggressive and resistant forms of cancer, aiming to transform cancer treatment.

Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

Treeline Biosciences is a biotechnology company focused on developing precision medicines for cancer and other serious diseases. Founded in 2021 and based in Stamford, Connecticut, the company uses a platform that integrates pathophysiology, genomics, and pattern recognition to identify therapeutic approaches that address unmet patient needs.

Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Orbital Therapeutics develops innovative RNA-based medicines to enhance global health. Its platform integrates RNA technology, delivery techniques, data analytics, and automation to create a broad portfolio of treatments for various diseases.

Vilya is a biotechnology company focused on developing innovative drugs that precisely target the underlying biology of diseases. By leveraging advanced computational techniques, Vilya aims to create a new class of medicines that can efficiently navigate uncharted chemical spaces and generate novel molecular structures. These structures, which are designed to possess essential drug-like properties, can range in size between small molecules and antibodies. Vilya's platform is engineered to improve the drug discovery process, enabling more effective treatments by facilitating the disruption of protein-protein interactions and ensuring optimal movement through biological membranes. Through its pioneering approach, Vilya is dedicated to advancing therapeutic options for patients.

Happy Health is a mission-driven technology company committed to transforming mental health awareness through the Happy Ring, the first wearable designed to measure your stress and mood 24/7.

Homeward delivers innovative rural health services for over 60 million Americans residing in rural communities. It employs multidisciplinary care teams offering both virtual and on-site care via mobile units, along with remote monitoring to enhance patient connections to high-quality, affordable healthcare.

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

Pheast Therapeutics is a cancer immunotherapy company developing macrophage-targeted therapies and innate immune checkpoint inhibitors to engage the body's innate immune response against cancer. The company focuses on agents that enhance macrophage phagocytosis and tumor cell elimination, including antibodies targeting CD24 to boost macrophage activity. Founded in 2020 and headquartered in Palo Alto, California, Pheast aims to offer innovative oncology treatments that complement existing therapies and improve patient outcomes.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Proof Diagnostics is a life sciences company focused on developing diagnostic tools and therapeutic applications. The company specializes in creating rapid diagnostic tests for infectious diseases, including a critical test for the detection of coronavirus infection. With a commitment to enhancing patient care, Proof Diagnostics designs and manufactures diagnostic kits that empower medical professionals to accurately and efficiently test patients for various infections. Additionally, the company is working on a smart, portable system aimed at expanding the capabilities of disease detection.

Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Nutcracker Therapeutics is a biotechnology company based in Emeryville, California, that develops and manufactures mRNA therapeutics using a proprietary microfluidic, biochip-based platform. Its ACORN system is a computer-controlled RNA manufacturing platform that starts with a nucleic acid sequence and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated single-use biochips. The company provides a push-button mRNA synthesis and formulation capability, enabling fully integrated production of mRNA therapies at scale and on demand. The platform combines advances in RNA biology with manufacturing concepts inspired by semiconductors to enable rapid discovery, development, and manufacturing of complex mRNA therapies and vaccines. By offering on-demand production and a scalable capability, Nutcracker Therapeutics aims to support healthcare teams to produce multimodal therapeutics at the point of care.

Feelmore Labs is a health and wellness technology company based in New York City, focused on developing innovative non-invasive wearable devices aimed at enhancing well-being. The company's products are designed to train and tune the nervous system by modulating the insula, a deep brain region that controls emotional responses. This approach helps users achieve a sense of calm, reduces stress and anxiety, and ultimately improves sleep patterns. By pioneering a new category of medical and consumer devices, Feelmore Labs seeks to transform how individuals experience and manage their health and wellness.

ONI specializes in super-resolution microscopy, making advanced imaging technology accessible to researchers worldwide. Its flagship product, the Nanoimager, offers easy access to techniques like dSTORM and PALM, enabling users to visualize molecules within living cells for enhanced biological research.

Transcenta Holding is a clinical-stage biopharmaceutical company that offers fully integrated capabilities in antibody discovery, research and development, manufacturing, and business development. The company concentrates on developing innovative antibody-based therapeutics for oncology and selected non-oncology indications, including bone and kidney disorders, with a pipeline that includes Osemitamab (TST001), TST002, TST003, TST006, MSB2311, MSB0254, TST808, and other candidates. Headquartered with multiple sites in China—Suzhou, Shanghai, Hangzhou, and Beijing—and with research and development and operations in the United States at Waltham and Princeton, Transcenta operates as a global biotherapeutics business. Founded in 2019, the company aims to advance therapeutic antibodies through discovery, development, and manufacturing to address unmet patient needs. Its business scope encompasses clinical research and trial services alongside its development programs, positioning it to accelerate pipeline progress and collaborate on global opportunities.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.

Slingshot Biosciences develops engineered synthetic cells to accelerate drug research and enable diagnostics and therapeutics. The company creates next-generation cellular tools that aim to simplify complex experiments, improve data standardization in cell analysis, and provide cost-effective solutions for research programs. Its work includes aligning cellular properties such as forward and side scatter of white blood cells to enable more consistent measurements and faster interpretation. By removing cold-chain barriers, Slingshot Biosciences seeks to broaden access to advanced diagnostics and therapeutics, supporting programs focused on neglected and rare diseases. Operating in the industrial synthetic biology space, the company concentrates on practical cellular technologies that can shorten development timelines and reduce costs for researchers.

ImmuneID is a precision immunology company that uses a proprietary platform to identify and therapeutically target millions of antibody interactions that drive immune diseases. The platform enables parallel, multiplexed, and unbiased analyses to develop therapeutics for autoimmunity, severe allergy, oncology, and infectious diseases, and helps researchers observe human immune responses throughout disease progression.

Founded in 2019, HiberCell is a biotechnology company based in New York. It develops therapeutics focused on preventing cancer relapse and metastasis by targeting adaptive stress pathways and immune modulation.

Interline Therapeutics is a drug discovery company that maps and modulates protein communities to reveal molecular mechanisms of disease and develop precision medicines. Using genomics, proteomics, structural biology, and computational chemistry, it analyzes signaling networks to identify genetically validated targets and design therapies that comprehensively correct dysfunctional protein communities. The company is based in South San Francisco and was established in 2020.

Ultivue develops multiplex biomarker assays for tissue phenotyping and digital pathology. Its products enable high-resolution fluorescent microscopy imaging, aiding life science research and potential clinical diagnostics.

Treeline Biosciences is a biotechnology company focused on developing precision medicines for cancer and other serious diseases. Founded in 2021 and based in Stamford, Connecticut, the company uses a platform that integrates pathophysiology, genomics, and pattern recognition to identify therapeutic approaches that address unmet patient needs.

Jaguar Gene Therapy is developing gene therapy treatments for severe genetic diseases. Its clinical-stage pipeline focuses on neurodevelopmental disorders, Type 1 galactosemia, and Type 1 diabetes.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

OncoResponse is an immuno‑oncology biotechnology company that uses a proprietary human antibody platform to discover novel targets and develop fully human monoclonal antibodies for cancer treatment. By interrogating the adaptive immune system of patients who respond exceptionally well to checkpoint inhibition, the company identifies genuine human antibodies against high‑value targets linked with immunosuppressive myeloid biology. Its pipeline aims to alleviate tumor‑microenvironment immunosuppression and enhance immune activation, converting cold tumors into hot ones and providing new therapeutic options for patients.

Interline Therapeutics is a drug discovery company that maps and modulates protein communities to reveal molecular mechanisms of disease and develop precision medicines. Using genomics, proteomics, structural biology, and computational chemistry, it analyzes signaling networks to identify genetically validated targets and design therapies that comprehensively correct dysfunctional protein communities. The company is based in South San Francisco and was established in 2020.

ImmuneID is a precision immunology company that uses a proprietary platform to identify and therapeutically target millions of antibody interactions that drive immune diseases. The platform enables parallel, multiplexed, and unbiased analyses to develop therapeutics for autoimmunity, severe allergy, oncology, and infectious diseases, and helps researchers observe human immune responses throughout disease progression.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Cytrellis Biosystems, Inc. is a clinical stage medical technology company focused on designing and developing innovative devices for dermatology, scar reduction, and aesthetic medicine. Founded in 2011 and headquartered in Sherborn, Massachusetts, the company aims to address age-related skin changes through non-surgical solutions. Its products are specifically engineered to remove sagging skin without the need for invasive procedures or scarring, thereby offering aesthetic practitioners enhanced capabilities to improve the appearance of aging skin. Cytrellis Biosystems is dedicated to advancing the field of aesthetic medicine with its cutting-edge technologies.

Altos Labs is a biotechnology company dedicated to cellular rejuvenation programming aimed at restoring cell health and resilience. The organization seeks to develop innovative approaches to medicine that can reverse diseases, injuries, and disabilities. By uniting a community of prominent scientists, clinicians, and industry leaders, Altos Labs fosters collaboration across its operations in the San Francisco Bay Area, San Diego, and Cambridge, UK, while also engaging in significant partnerships in Japan. Through its research and initiatives, the company aspires to transform the landscape of medical treatment.